Each of the five gadolinium-based contrast agents that are used in the U.S. were approved between 1988 and 2004. Before approval, more than 3000 patients were studied in clinical trials, and the most common serious side effect was an allergic reaction. Other side effects included skin conditions such as itching, rash, hives, and swelling. Additionally, some patients experienced irritation to the veins in which the chemicals are injected and formed blood clots.

Signs of nephrogenic systemic fibrosis were not noted during clinical trials because patients with severe kidney conditions are not usually subjects in clinical trials. However, since gadolinium is excreted through the kidney, patients with kindey problems faced severe complications in response to the drug. 

If you or someone you know has developed nephrogenic systemic fibrosis, known as NSF, or another serious condition after exposure to a gadolinium-based contrast agent during an MRI, contact a gadolinium attorney from Williams Kherkher at 800-761-3187 for help.